The UK Competition Authority fines two drug companies for overcharging the National Health Service (Auden Mckenzie / Actavis / AMCo / Waymade)

CMA finds drug companies overcharged NHS* The CMA has imposed fines totalling over £260 million for competition law breaches in relation to the supply of hydrocortisone tablets. Prices of life-saving hydrocortisone tablets rose by over 10,000%.Pharma firms bought off potential rivals to avoid them competing with their own versions of the drug and preserve their ability to increase prices. The fines are the result of a Competition and Markets Authority (CMA) investigation into the conduct of several pharmaceutical firms which found that Auden Mckenzie and Actavis UK (now known as Accord-UK) charged the NHS excessively high prices for hydrocortisone tablets for almost a decade. To protect its position as sole provider of the tablets, and enable it to continue to increase prices, Auden

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • United Kingdom’s Competition Authority - CMA (London)

Quotation

UK Competition Authority, The UK Competition Authority fines two drug companies for overcharging the National Health Service (Auden Mckenzie / Actavis / AMCo / Waymade), 15 July 2021, e-Competitions July 2021 - II, Art. N° 101627

Visites 84

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues